Patents by Inventor Sun Ah Jun

Sun Ah Jun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220389010
    Abstract: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions: in Chemical Formula 1, R1 to R3 are as defined in the present specification.
    Type: Application
    Filed: November 25, 2020
    Publication date: December 8, 2022
    Inventors: Ji Duck Kim, Sun Ah Jun, Nam Youn Kim, In Woo Kim, Hyae Jung Hyun, Joon Seok Park
  • Patent number: 11339167
    Abstract: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and the compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions: wherein: R1 is pyrazolyl, isooxazolyl, isothiazolyl, phenyl, or benzothiazolyl, wherein the pyrazolyl, isoxazolyl, isothiazolyl, phenyl, or benzothiazolyl is optionally substituted with one Ra substituent; R2 is H, halogen, CN, or C1-5 alkyl; and Ra is C1-5 alkyl, C1-5 haloalkyl, C1-5 hydroxyalkyl, C3-6 cycloalkyl, tetrahydropyranyl, piperidinyl, or morpholino.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: May 24, 2022
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: In Woo Kim, Sun Ah Jun, Nam Youn Kim, Jun Hee Lee
  • Patent number: 11084823
    Abstract: The present invention relates to a compound represented by the Chemical Formula 1 defined in the present specification, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: August 10, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: In Woo Kim, Ja Kyung Yoo, Ji Duck Kim, Sun Ah Jun, Jun Hee Lee
  • Publication number: 20210130358
    Abstract: The present invention relates to a compound represented by the Chemical Formula 1 defined in the present specification, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.
    Type: Application
    Filed: March 19, 2018
    Publication date: May 6, 2021
    Inventors: In Woo Kim, Ja Kyung Yoo, Ji Duck Kim, Sun Ah Jun, Jun Hee Lee
  • Patent number: 10961247
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 30, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: In Woo Kim, Mi Ryeong Han, Jakyung Yoo, Yun Ju Oh, Ji Duck Kim, Nam Youn Kim, Sun Ah Jun, Jun Hee Lee, Joon Seok Park
  • Publication number: 20200317673
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 8, 2020
    Inventors: In Woo Kim, Mi Ryeong Han, Jakyung Yoo, Yun Ju Oh, Ji Duck Kim, Nam Youn Kim, Sun Ah Jun, Jun Hee Lee, Joon Seok Park
  • Publication number: 20200308177
    Abstract: The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatm ent of diseases which are associated with kinase inhibitory actions.
    Type: Application
    Filed: December 28, 2018
    Publication date: October 1, 2020
    Inventors: In Woo Kim, Sun Ah Jun, Nam Youn Kim, Jun Hee Lee
  • Patent number: 10590078
    Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 17, 2020
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Duck Kim, Hyung Geun Lee, Inwoo Kim, Sun Ah Jun, Myunggi Jung, Hyo Shin Kim
  • Patent number: 10227338
    Abstract: The invention relates to a compound represented by Chemical Formula 1, below, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound or salt. The compound of the invention or pharmaceutically acceptable salts thereof can be used for the prevention or treatment of sodium channel blocker-related diseases.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: March 12, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Hyung-Geun Lee, Il-Hwan Kim, Myunggi Jung, Hyo Shin Kim, Chun Ho Lee, Sun Ah Jun, Ji Sung Yoon, Sung-Young Kim
  • Publication number: 20180346459
    Abstract: The present invention relates to a compound represented by Chemical Formula, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of sodium channel blocker-related diseases.
    Type: Application
    Filed: November 11, 2016
    Publication date: December 6, 2018
    Inventors: Hyung-Geun LEE, Il-Hwan KIM, Myunggi JUNG, Hyo Shin KIM, Chun Ho LEE, Sun Ah JUN, Ji Sung YOON, Sung-Young KIM
  • Publication number: 20180297948
    Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).
    Type: Application
    Filed: February 11, 2016
    Publication date: October 18, 2018
    Inventors: Ji Duck KIM, Hyung Geun LEE, Inwoo KIM, Sun Ah JUN, Myunggi JUNG, Hyo Shin KIM
  • Patent number: 9376429
    Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and the use thereof. A compound represented by formula 1 according to the invention, or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof may be effectively used for the prevention or treatment of pain, for example, acute pain, chronic pain, neuropathic pain, post-surgery pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, or paroxysmal extreme pain disorder (PEPD).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: June 28, 2016
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ha Young Kim, In Woo Kim, Sun Ah Jun, Yun Soo Na, Hyung Geun Lee, Min Jae Cho, Jun Hee Lee, Hyo Shin Kim, Yun Soo Yoon, Kyung Ha Chung, Ji Duck Kim
  • Patent number: 9328115
    Abstract: Provided is a process for the preparation of meropenem trihydrate in high purity and high yield, including using a dry methanol solvate of meropenem, which can remarkably reduce the amount of residual solvents in the resulting product, thereby obtain meropenem trihydrate in high purity.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: May 3, 2016
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Soo-Jin Choi, Byung-Goo Lee, Hee-Kyoon Yoon, Sung-Woo Park, Sun-Ah Jun, Kyung-Ho Lee, Byung-Jo Lim
  • Patent number: 9233963
    Abstract: The present invention relates to an improved method for synthesizing meropenem trihydrate[(1R,5S,6S)-2-[((2?S,4?S)-2?-dimethylaminocarbozyl)pyrrolidin-4?-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid, trihydrate], which is a novel carbapenem antibiotic.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: January 12, 2016
    Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., DAEWOONG BIO, INC.
    Inventors: Yoon Seok Song, Sung Woo Park, Yeon Jung Yoon, Hee Kyoon Yoon, Seong Cheol Moon, Byung Goo Lee, Soo Jin Choi, Sun Ah Jun
  • Publication number: 20150353554
    Abstract: Provided is a process for the preparation of meropenem trihydrate in high purity and high yield, including using a dry methanol solvate of meropenem, which can remarkably reduce the amount of residual solvents in the resulting product, thereby obtain meropenem trihydrate in high purity.
    Type: Application
    Filed: November 21, 2013
    Publication date: December 10, 2015
    Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Soo-Jin CHOI, Byung-Goo LEE, Hee-Kyoon YOON, Sung-Woo PARK, Sun-Ah JUN, Kyung-Ho LEE, Byung-Jo LIM
  • Publication number: 20150336944
    Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and the use thereof. A compound represented by formula 1 according to the invention, or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof may be effectively used for the prevention or treatment of pain, for example, acute pain, chronic pain, neuropathic pain, post-surgery pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, or paroxysmal extreme pain disorder (PEPD).
    Type: Application
    Filed: October 15, 2013
    Publication date: November 26, 2015
    Inventors: Ha Young Kim, In Woo Kim, Sun Ah Jun, Yun Soo Na, Hyung Geun Lee, Min Jae Cho, Jun Hee Lee, Hyo Shin Kim, Yun Soo Yoon, Kyung Ha Chung, Ji Duck Kim
  • Publication number: 20120065392
    Abstract: The present invention relates to an improved method for synthesizing meropenem trihydrate [(1R,5S,6S)-2-[((2?S,4?S)-2?-dimethylaminocarbozyl)pyrrolidin-4?-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid, trihydrate], which is a novel carbapenem antibiotic.
    Type: Application
    Filed: March 11, 2010
    Publication date: March 15, 2012
    Applicants: DAEWOONG BIO INC., DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Yoon Seok Song, Sung Woo Park, Yeon Jung Yoon, Hee Kyoon Yoon, Seong Cheol Moon, Byung Goo Lee, Soo Jin Choi, Sun Ah Jun